Figure 1.
Strategy of the global programme to eliminate lymphatic filariasis.
Interrupting transmission through mass drug administration (MDA) and morbidity management and disability prevention (MMDP) in populations with LF [21].
Figure 2.
Selected opportunities for integrating lymphatic filariasis activities into programmes for other diseases [21].
Figure 3.
Schematic diagram to demonstrate partnership in GPELF.
National govt: National governments; Pharma: pharmaceutical companies.
Figure 4.
Global view of MDA progress and projection by programme steps, 2000–2021 (updated from [2]).
Figure 5.
Country-wide MDA progress and projection by programme steps, 2000–2021.